Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate

NATICK, Mass., Oct. 14, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy Klobuchar (D-MN) and cosponsored by Sens. Richard Burr (R-NC) and Michael Bennet (D-CO).  The legislation is intended to streamline the medical device review and approval process, reduce regulatory delays and help new medical technologies safely and more expeditiously reach patients.

Boston Scientific commends Senators Klobuchar, Burr and Bennet for their thoughtful leadership in introducing this new legislation designed to streamline the Food and Drug Administration's regulation of medical devices.  This bill is an important step in transforming the process of bringing life-enhancing and life-saving medical technologies to market in a safe and more efficient and predictable manner. 

Boston Scientific looks forward to collaborating with the sponsoring senators and other Members of Congress on this important piece of legislation.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

CONTACT:

Erik Kopp


508-650-8660 (office)


Media Relations


Boston Scientific Corporation


[email protected]




Sean Wirtjes


508-652-5305 (office)


Investor Relations


Boston Scientific Corporation


[email protected]



SOURCE Boston Scientific Corporation

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.